Breakthrough in Lung Cancer Treatment: Researchers Develop Nanoparticle Therapy

Strategic Insights -

Researchers at Jiangsu University in Jiangsu, People's Republic of China, have made a significant discovery in the field of oncology, developing a nanoparticle therapy that enhances the therapeutic potential of curcumin for lung cancer treatment. The study, which received financial support from the Medical Education Collaborative Innovation Fund of Jiangsu University, utilized a unique approach by incorporating transferrin (Tf) into magnetic nanoparticles to improve curcumin's delivery and efficacy.

The newly developed Tf-MNP-PEG-PLGA-Cur nanoparticles demonstrated a small size, biphasic release pattern, and longer half-life, making them a promising polymeric sustained-release curcumin preparation. In vitro studies showed that the nanoparticles had a high efficiency of drug release and uptake by A549 cells, while in vivo experiments demonstrated their ability to accumulate in tumor sites and inhibit tumor growth. The results of this research suggest that the Tf-MNP-PEG-PLGA-Cur nanoparticles could be a potential game-changer in lung cancer treatment.

Key Takeaways:

  • Researchers at Jiangsu University have developed a novel nanoparticle therapy (Tf-MNP-PEG-PLGA-Cur) that enhances the therapeutic potential of curcumin for lung cancer treatment.
  • The nanoparticles have a small size (137.39 ± 3.72 nm) and biphasic release pattern, making them a promising polymeric sustained-release curcumin preparation.
  • In vitro studies demonstrated a high efficiency of drug release and uptake by A549 cells, while in vivo experiments showed tumor accumulation and inhibition of tumor growth.
  • The study was financially supported by the Medical Education Collaborative Innovation Fund of Jiangsu University and received peer-review.
  • The researchers involved in this study include Hui Ding, Gengsheng Shi, Wenqin Yin, Jing Luo, Linluo Zhang, Song Lin, and Yuan He.

Statistics:

  • Nanoparticles size: 137.39 ± 3.72 nm (PDI 0.224 ± 0.010)
  • Half-life: Prolonged (no specific number provided)
  • Drug release pattern: Biphasic
  • Efficiency of drug release: High (no specific number provided)
  • A549 cell uptake: High (no specific number provided)
  • Tumor growth inhibition: In vivo experiments demonstrated a significant reduction in tumor growth
  • Funding: Supported by the Medical Education Collaborative Innovation Fund of Jiangsu University
  • Peer-review: Yes

Sources:

  • NewsRx. New Lung Cancer Study Findings Have Been Reported by Investigators at Jiangsu University (Development and Evaluation of Tumor-targeting Curcumin-loaded Magnetic Nanoparticles Based On Peg-plga and Transferrin for Anti-lung Cancer Therapy). Health & Medicine Week. July 18, 2025; p 2877.
  • Ding, H., et al. (2025). Development and Evaluation of Tumor-targeting Curcumin-loaded Magnetic Nanoparticles Based On Peg-plga and Transferrin for Anti-lung Cancer Therapy. Materials Today Communications, 47.